Exploration of Targeted Anti-tumor Therapy

Table 1

Comparison of clinico-pathological features between patients with and without sarcopenia

Parameter		Total	Pre-chemotherapy sarcopenia		Total	Post-chemotherapy sarcopenia		P-value (sex)
Parameter		Total	Yes	No	Total	Yes	No	Baseline	Post-chemotherapy
BMI	< 18.5%	285	42	14	-	-	-	0	-
	18.5–24.99%		89	72
	25.0–29.99%		26	35
	≥ 30%		5	2
Age	≤ 65 Years	285	141	111	274	150	95	0.40	0.12
Age	> 65 Years	285	21	12	274	22	7	0.40	0.12
Smoker	Yes	285	41	18	274	43	11	0.02	0
Smoker	No	285	121	105	274	129	91	0.02	0
SMD	Good (> 36.62)	285	34	66	274	42	59	0	0
SMD	Poor (≤ 36.62)	285	128	57	274	130	43	0	0
Gender	Male	285	115	44	274	121	29	0	0
Gender	Female	285	47	79	274	51	73	0	0
ALI	Good (> 28.02)	285	55	53	274	-	-	0.12	-
ALI	Poor (≤ 28.02)	285	107	70	274	-	-	0.12	-
mALI	Good (> 55.33)	285	54	58	274	80	67	0.02	0.02
mALI	Poor (≤ 55.33)	285	108	65	274	92	35	0.02	0.02
NLR	Good (≤ 3)	285	55	55	274	88	63	0.06	0.08
NLR	Poor (> 3)	285	107	68	274	84	39	0.06	0.08
Chemotherapy regimen received	Geftinib	285	78	65	-	-	-	0.43	-
Chemotherapy regimen received	Pemetrexed plus platins	285	84	58	-	-	-	0.43	-
Grades of drug toxicity	High grade	273	87	83	-	-	-	0.06	-
Grades of drug toxicity	Low grade	273	65	38	-	-	-	0.06	-
Performance status	0–1	285	150	118	-	161	97	0.23	0.61
Performance status	≥ 2	285	12	5	-	11	5	0.23	0.61
Progression	Yes	285	118	92		-	-	0.71
Progression	No	285	44	31		-	-	0.71
Final status	Alive	285	25	42	-	-	-	0	-
Final status	Dead	285	137	81	-	-	-	-	-

-: not applicable. Bold values indicate significant P-values